reported their pooled analysis of data on BRAF V600-mutant relapsed/refractory LCH patients enrolled across two open label phase I/II pediatric trials of either dabrafenib monotherapy or dabrafenib with trametinib (132). Here, BRAF is linked to Langerhans cell histiocytosis.